As we continue to strengthen our position in the life sciences sector, today we are proud to announce the acquisition of Diabtec LLC, a subsidiary of Julphar. This strategic acquisition enables us to address critical global challenges including the growing prevalence of diabetes, and demand for microbial based products such as insulin analogues and GLP-1s to treat such conditions locally and abroad.
KELIX bio, a Mubadala company, has acquired DiabTec LLC, further strengthening our position in the MENA life sciences sector. This acquisition marks the fifth strategic move for KELIX bio since its acquisition in March 2024, enhancing its biomanufacturing capabilities. DiabTec’s state-of-the-art facility, which is built to EU/US FDA standards and is currently the only one in the GCC of this kind, bolsters Mubadala’s efforts to advance local manufacturing and support global insulin supply.